Kurzfassung

A phase III, multicenter, randomized, open-label, controlled study to evaluate the efficacy, safety, and pharmacokinetics of Atezolizumab given in combination with Cabozantinib versus Docetaxel monotherapy in patients with metastatic non small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy